Participated · Equity · Mar 2024

Syrenna has developed the WaterDrone, a sealed robotic platform that controls its depth with a swim-bladder and maintains geographic position via a proprietary tether to provide persistent, near–real-time subsea sensing. The device carries sensors for temperature, salinity, microplastics and other marine metrics, runs on a battery rated for a full year of operation, and is being developed to recharge at the surface and transmit data via Iridium satellites. Syrenna completed a next-generation hardware version and has run pilots in Oslofjord and offshore tests to 180 meters, with longer-term trials underway. The company plans to sell robots directly to customers and to release some collected data publicly through partners such as Hub Ocean. Operating since 2022 out of Oslo, Syrenna has been engineering‑centric in hiring and is now expanding toward productization and full‑stack developer hiring to improve visualizations and BI integration.

Led · Grant · Dec 2023

Hemispherian AS is a Norwegian preclinical pharmaceutical company based in Oslo focused on developing a novel class of small-molecule drugs called GLIX. GLIX compounds target the TET2 enzyme and activate the DNA damage response to induce cancer cell death. The company's lead candidate, GLIX1, is in late-stage preclinical development for glioblastoma, and the company is advancing GLIX5 toward clinical use for platinum-resistant ovarian cancers. The Research Council of Norway awarded Hemispherian a NOK 16 million grant, earmarked for development of drug candidates addressing platinum-resistant ovarian cancers. CEO Zeno Albisser said the team is dedicated to advancing GLIX5 toward clinical use and developing therapies that will make a tangible difference for cancer patients. Hemispherian is a preclinical pharmaceutical company developing a novel class of small molecule drugs called GLIX that target the TET2 enzyme. GLIX compounds activate the DNA damage response, leading to cancer cell death. The company’s lead compound, GLIX1, is in late-stage preclinical development for glioblastoma multiforme. Hemispherian is also developing a companion diagnostic to support patient selection for optimal response to GLIX1. The company is led by CEO Zeno Albisser and is based in Oslo, Norway. It plans to use recent funding to support drug development, expand its preclinical pipeline, and advance its lead therapeutic compounds toward clinical development. Hemispherian is a preclinical pharmaceutical company based in Oslo focused on developing GLIX small-molecule drugs that target the TET2 enzyme and activate the DNA damage response to induce cancer cell death. Its lead asset, GLIX1, is in late-stage preclinical development for the treatment of glioblastoma. The company is led by CEO Zeno Albisser and CSO Adam Robertson, PhD. Hemispherian raised financing to advance GLIX1 into clinical testing. The funds will be used to progress GLIX1 through a phase I and phase II clinical trial. Financial details in the articles indicate a mix of grant and equity financing supporting these development plans. Hemispherian is an Oslo-based preclinical pharmaceutical company developing a novel class of small-molecule drugs called GLIX that target the TET2 enzyme and activate the DNA damage response to induce cancer cell death. Its lead candidate, GLIX1, is in late-stage preclinical development for glioblastoma multiforme. The company is also developing a companion diagnostic to support patient selection for optimal response to GLIX1. Hemispherian intends to use the newly raised funds to expand its drug development activities and its preclinical pipeline and to move lead compounds toward clinical development. The firm recently refreshed its board with new members to support these development efforts.

Participated · Grant · Nov 2022

Wastefront operates pyrolytic reactors that use thermal depolymerisation (pyrolysis) to break down end-of-life tyres and produce recovered carbon black (rCB) and pyrolysis oil. Its South Tyneside (Sunderland) plant is a £100 million project planned to be fully operational by 2025 and will convert material equivalent to 20% of the UK’s annual ELT supply into rCB. Integrating Wastefront’s rCB into new tyres is projected to reduce emissions for each tyre by 80%. The company aims to scale via licensing its ‘‘Wastefront Blueprint’’ and deploying multiple plants globally in partnership with industrial players. Wastefront has entered a strategic partnership with VTTI that includes an investment and commitments to develop additional sites. The market for carbon black and related products is expected to grow from $13 billion in 2022 to $18 billion by 2029, a tailwind cited in the announcement. Wastefront emphasizes turning a large global waste problem into saleable products sought in the energy transition. Wastefront operates pyrolytic reactors that use thermal depolymerisation (pyrolysis) to break down end-of-life tyres and produce recovered carbon black (rCB) and tyre-derived oil (TDO). The company is collaborating with Swedish engineering firm Hulteberg Chemistry & Engineering on HYFUEL, a project to purify pyrolysis oil for use as a renewable biofuel. HYFUEL’s optimised tyre pyrolysis oil can substitute for diesel without further refining, enabling lower-temperature applications, cost savings, and reduced carbon emissions. Wastefront has secured a €2 million grant and total project funding of €2.076 million to advance HYFUEL's use cases. The firm is building a £100 million tyre recycling plant in Sunderland, Northern England, due to be fully operational by 2025. The South Tyneside plant aims to process about 20% of the UK's end-of-life tyres and produce rCB, which Wastefront says can reduce emissions for tyres made with its rCB by 80%.

Participated · Seed · Jul 2021

ClexBio is an Oslo‑based startup developing bioengineered human blood vessels for transplant by manipulating living cells at the microscale using its proprietary CLEX technology. The company is led by Co‑Founder and CEO Dr. Armend G. Håti and Co‑Founder and CSO Dr. Manuel Schweikle. ClexBio is already commercializing early R&D applications in partnership with Cambridge‑based Sphere Fluidics. It raised US$2.2M in seed financing to expand operations and continue development efforts. The financing consisted of US$1.2M from angel investors across Europe and Asia and US$1M in non‑dilutive grants. The company intends to use the funds to continue to expand operations and development efforts.

Participated · Grant · Jun 2013

The article reports that Circio has secured 300 million kroner in funding. The piece does not describe the company’s products, services, or business model. There are no operating metrics, revenue, or user figures provided. The report also omits details on the company’s founding year or location. No plans tied to the new capital were specified in the article.